Application of novel oral anticoagulants in patients with liver cirrhosis
- VernacularTitle:新型口服抗凝药物在肝硬化患者中的应用
- Author:
Jiao QUAN
1
;
Tongyu WANG
1
;
Yun JIN
1
;
Sheng LI
1
;
Ning ZHOU
1
Author Information
- Publication Type:Review
- Keywords: Liver Cirrhosis; Anticoagulants; Pharmacokinetics
- From: Journal of Clinical Hepatology 2025;41(10):2149-2153
- CountryChina
- Language:Chinese
- Abstract: Liver cirrhosis is a common chronic progressive liver disease， and such patients often have coagulation disorders， which may lead to thrombotic and hemorrhagic events. While traditional anticoagulant therapies have various limitations， the emergence of novel oral anticoagulants （NOAC） provides new options for anticoagulation treatment in patients with liver cirrhosis. This article comprehensively reviews the application of NOAC in patients with liver cirrhosis， discusses their advantages and potential risks， analyzes their pharmacokinetic and pharmacodynamic characteristics， and evaluates their efficacy and safety in the prevention and treatment of cirrhosis-associated thrombosis based on clinical evidence， in order to provide a reference for clinical decision-making.
